• Neharika Gupta
• Amarish Kumar Sharma

Pancreatic ductal adenocarcinoma (PDAC), most common pancreatic epithelial malignancy, is found to have a poor prognosis as compared to other solid tumors and is believed to become one of the major cause of cancer related deaths in future. Most of cases which are being diagnosed are of people above 65 and 60% of these cases are at an advanced level. Moreover, 5 year survival rate is not more than 10%. PDAC is intrinsically resistant to chemotherapeutic drugs due to a dense stromal reaction which affects the delivery of drugs. So, surgery serves as the only treatment for early pancreatic cancer stages. For advanced and metastatic stage, treatment is in the form of adjuvant chemotherapy (with or without radiotherapy). There is a need to develop novel molecular markers for the clinical management of pancreatic cancer patients because the existing markers like CA19-9 shows some limitations, thus there is no marker available for routine use. Advancement in the field of molecular biology have increased our understanding on pathogenesis of pancreatic adenocarcinomas. Mutations in K-ras oncogene and tumor suppressor genes are found to have a link with pancreatic cancer.

Diabetes, anti-diabetic, cardiovascular diseases, glucose levels, β-cells.

"Pathophysiology of Pancreatic Adenocarcinoma", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.5, Issue 12, page no.497-502, December 2018, Available :http://www.jetir.org/papers/JETIRDT06065.pdf

"Pathophysiology of Pancreatic Adenocarcinoma", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.5, Issue 12, page no. pp497-502, December 2018, Available at : http://www.jetir.org/papers/JETIRDT06065.pdf